IVVD
Invivyd, Inc.
Price Chart
Latest Quote
$0.88
-0.05 (-5.55%)
Current Price
| Previous Close | $0.93 |
| Open | $0.93 |
| Day High | $0.96 |
| Day Low | $0.87 |
| Volume | 3,482,409 |
Stock Information
| Shares Outstanding | 294.61M |
| Total Debt | $8.63M |
| Cash Equivalents | $184.15M |
| Revenue | $55.87M |
| Net Income | $-77.60M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $258.90M |
| EPS (TTM) | $-0.29 |
| Exchange | NGM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $83.37M |
| Sales | $55.87M |
| Income | $-77.60M |
| Book/sh | $0.72 |
| Cash/sh | $0.63 |
| Employees | 122 |
Financial Ratios
| Quick Ratio | 6.20 |
| Current Ratio | 6.47 |
| Debt/Eq | 4.25 |
Returns & Margins
| ROA | -29.59% |
| ROE | -60.34% |
| Gross Margin | 92.94% |
| Operating Margin | -313.85% |
| Profit Margin | -138.90% |
Ownership
| Insider Ownership | 7.07% |
| Institutional Ownership | 83.88% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -1.52 |
| P/S | 4.63 |
| P/B | 1.22 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $10.00 |
Technical Indicators
| SMA20 | $0.98 |
| SMA50 | $1.23 |
| SMA200 | $1.70 |
| RSI | 32.83 |
| ATR | 0.1058 |
| Shares Float | 214.30M |
| Short Float | 11.60% |
| Short Ratio | 10.43 |
| Volatility | 0.63 |
| Rel Volume | 0.62 |
Performance History
| Week | -5.61% |
| Month | -20.11% |
| Quarter | -43.67% |
| 6 Months | -69.49% |
| YTD | -64.85% |
| Year | +17.17% |
| 3 Years | -25.53% |
| 10 Years | -95.79% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-25 | $0.88 | 3,482,409 |
| 2026-06-24 | $0.93 | 2,941,300 |
| 2026-06-23 | $0.94 | 1,401,500 |
| 2026-06-22 | $0.91 | 4,104,600 |
| 2026-06-18 | $0.97 | 21,078,800 |
| 2026-06-17 | $0.93 | 4,336,500 |
| 2026-06-16 | $0.89 | 5,002,700 |
| 2026-06-15 | $0.87 | 13,276,200 |
| 2026-06-12 | $0.77 | 8,337,100 |
| 2026-06-11 | $0.81 | 13,681,500 |
| 2026-06-10 | $0.90 | 5,436,800 |
| 2026-06-09 | $0.99 | 5,413,400 |
| 2026-06-08 | $1.02 | 2,612,300 |
| 2026-06-05 | $1.03 | 4,974,600 |
| 2026-06-04 | $1.11 | 3,756,000 |
| 2026-06-03 | $1.10 | 2,865,100 |
| 2026-06-02 | $1.14 | 1,823,200 |
| 2026-06-01 | $1.22 | 2,432,800 |
| 2026-05-29 | $1.14 | 3,395,300 |
| 2026-05-28 | $1.13 | 2,739,900 |
| 2026-05-27 | $1.13 | 2,462,500 |
| 2026-05-26 | $1.10 | 2,217,400 |
About Invivyd, Inc.
Invivyd, Inc., together with its subsidiaries, engages in the research, development, commercialization, and sale of antibody therapies for the prevention and treatment of viral infectious diseases in the United States. The company offers Pemivibart, a half-life extended investigational monoclonal antibody for the pre-exposure prophylaxis prevention of COVID-19 in adults and adolescents through injection under the PEMGARDA brand. It also develops VYD2311, a monoclonal antibody, which is in Phase III clinical trial for the prevention and treatment of SARS-CoV-2 virus; and VBY329, a monoclonal antibody, which is in pre-clinical trial stage for the prevention and treatment of respiratory syncytial virus and measles in neonates, infants, and children. It has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in New Haven, Connecticut.
đ° Latest News
Invivyd (IVVD) Doses First Participants in Phase 3 Trial for VYD2311
Insider Monkey âĸ 2026-06-19T07:00:34Z
Invivyd doses first participants in Phase 3 COVID-19 trial
Proactive âĸ 2026-06-09T16:22:00Z
Invivyd Doses First Participants in Phase 3 Trial of COVID-19 Antibody VYD2311
MT Newswires âĸ 2026-06-09T12:15:06ZThis Invivyd Insider Increased Their Holding In The Last Year
Simply Wall St. âĸ 2026-06-06T13:11:31Z
Invivyd (IVVD): 10 Best NASDAQ Stocks Under $5 to Buy Right Now
Insider Monkey âĸ 2026-05-18T04:49:32Z
Invivyd Inc (IVVD) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and Strategic Investments
GuruFocus.com âĸ 2026-05-14T23:01:35ZInvivyd Q1 Earnings Call Highlights
MarketBeat âĸ 2026-05-14T16:15:47Z
Invivyd, Inc. (IVVD) Reports Q1 Loss, Lags Revenue Estimates
Zacks âĸ 2026-05-14T12:15:02Z
Upstream Bio, Inc. (UPB) Reports Q1 Loss, Beats Revenue Estimates
Zacks âĸ 2026-05-13T12:20:03Z
TELA Bio, Inc. (TELA) Reports Q1 Loss, Beats Revenue Estimates
Zacks âĸ 2026-05-12T21:15:02Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $3,747,000 | $1,618,000 | $0 | - |
| Cost Of Revenue | $3,747,000 | $1,618,000 | $0 | - |
| Total Revenue | $53,426,000 | $25,384,000 | $0 | $0 |
| Operating Revenue | $53,426,000 | $25,384,000 | $0 | $0 |
| Expenses | ||||
| Total Expenses | $108,986,000 | $202,260,000 | $207,783,000 | $226,258,000 |
| Other Income Expense | $3,071,000 | $6,951,000 | $9,140,000 | $-15,059,000 |
| Other Non Operating Income Expenses | $3,071,000 | $6,951,000 | $14,115,000 | $6,714,000 |
| Operating Expense | $105,239,000 | $200,642,000 | $207,783,000 | $226,258,000 |
| General And Administrative Expense | $66,931,000 | $63,388,000 | $49,125,000 | $47,044,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-52,489,000 | $-169,925,000 | $-198,643,000 | $-241,317,000 |
| Normalized Income | $-52,489,000 | $-169,925,000 | $-193,668,000 | $-219,544,000 |
| Net Income From Continuing And Discontinued Operation | $-52,489,000 | $-169,925,000 | $-198,643,000 | $-241,317,000 |
| Total Operating Income As Reported | $-55,560,000 | $-176,876,000 | $-212,758,000 | $-248,031,000 |
| Net Income Common Stockholders | $-52,489,000 | $-169,925,000 | $-198,643,000 | $-241,317,000 |
| Net Income | $-52,489,000 | $-169,925,000 | $-198,643,000 | $-241,317,000 |
| Net Income Including Noncontrolling Interests | $-52,489,000 | $-169,925,000 | $-198,643,000 | $-241,317,000 |
| Net Income Continuous Operations | $-52,489,000 | $-169,925,000 | $-198,643,000 | $-241,317,000 |
| Pretax Income | $-52,489,000 | $-169,925,000 | $-198,643,000 | $-241,317,000 |
| Operating Income | $-55,560,000 | $-176,876,000 | $-207,783,000 | $-226,258,000 |
| Gross Profit | $49,679,000 | $23,766,000 | $0 | - |
| Special Income Charges | - | $0 | $-4,975,000 | $-4,400,000 |
| Per Share | ||||
| Diluted EPS | $-0.30 | $-1.43 | $-1.81 | $-2.23 |
| Basic EPS | $-0.30 | $-1.43 | $-1.81 | $-2.23 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-53,453,000 | $-173,763,000 | $-200,780,000 | $-204,023,000 |
| Reconciled Depreciation | $2,107,000 | $3,113,000 | $2,028,000 | $462,000 |
| EBITDA (Bullshit earnings) | $-53,453,000 | $-173,763,000 | $-205,755,000 | $-225,796,000 |
| EBIT | $-55,560,000 | $-176,876,000 | $-207,783,000 | $-226,258,000 |
| Diluted Average Shares | $172,212,902 | $118,555,073 | $109,526,053 | $108,268,289 |
| Basic Average Shares | $172,212,902 | $118,555,073 | $109,526,053 | $108,268,289 |
| Diluted NI Availto Com Stockholders | $-52,489,000 | $-169,925,000 | $-198,643,000 | $-241,317,000 |
| Research And Development | $38,308,000 | $137,254,000 | $158,658,000 | $179,214,000 |
| Selling General And Administration | $66,931,000 | $63,388,000 | $49,125,000 | $47,044,000 |
| Other Gand A | $35,675,000 | $33,479,000 | $21,802,000 | $25,891,000 |
| Salaries And Wages | $31,256,000 | $29,909,000 | $27,323,000 | $21,153,000 |
| Total Unusual Items | - | $0 | $-4,975,000 | $-21,773,000 |
| Total Unusual Items Excluding Goodwill | - | $0 | $-4,975,000 | $-21,773,000 |
| Other Special Charges | - | - | $4,975,000 | $4,400,000 |
| Gain On Sale Of Security | - | - | - | $-17,373,000 |
Fetched: 2026-06-22
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $241,540,000 | $67,539,000 | $177,468,000 | $355,970,000 |
| Total Assets | $276,883,000 | $129,515,000 | $229,181,000 | $383,167,000 |
| Total Non Current Assets | $29,416,000 | $28,834,000 | $4,300,000 | $6,250,000 |
| Other Non Current Assets | $25,609,000 | $25,941,000 | $175,000 | $191,000 |
| Current Assets | $247,467,000 | $100,681,000 | $224,881,000 | $376,917,000 |
| Other Current Assets | $1,454,000 | $3,726,000 | - | - |
| Prepaid Assets | $4,466,000 | $16,437,000 | $23,307,000 | $4,549,000 |
| Inventory | $263,000 | $0 | - | - |
| Receivables | $14,595,000 | $11,169,000 | $933,000 | $377,000 |
| Accrued Interest Receivable | $676,000 | $263,000 | $933,000 | $377,000 |
| Accounts Receivable | $13,919,000 | $10,906,000 | $0 | - |
| Cash Cash Equivalents And Short Term Investments | $226,689,000 | $69,349,000 | $200,641,000 | $371,991,000 |
| Cash And Cash Equivalents | $226,689,000 | $69,349,000 | $200,641,000 | $92,076,000 |
| Debt | ||||
| Total Debt | $2,494,000 | $1,304,000 | $2,165,000 | $3,724,000 |
| Long Term Debt And Capital Lease Obligation | $1,180,000 | $0 | $722,000 | $2,165,000 |
| Current Debt And Capital Lease Obligation | $1,314,000 | $1,304,000 | $1,443,000 | $1,559,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $35,343,000 | $61,976,000 | $51,713,000 | $27,197,000 |
| Total Non Current Liabilities Net Minority Interest | $1,180,000 | $0 | $1,422,000 | $2,166,000 |
| Current Liabilities | $34,163,000 | $61,976,000 | $50,291,000 | $25,031,000 |
| Other Current Liabilities | $52,000 | $27,000 | $35,000 | $44,000 |
| Payables And Accrued Expenses | $27,048,000 | $56,729,000 | $38,061,000 | $17,443,000 |
| Payables | $13,744,000 | $10,448,000 | $7,953,000 | $1,517,000 |
| Accounts Payable | $13,744,000 | $10,448,000 | $7,953,000 | $1,517,000 |
| Tradeand Other Payables Non Current | - | $0 | $0 | - |
| Other Non Current Liabilities | - | - | $700,000 | $1,000 |
| Equity | ||||
| Common Stock Equity | $241,540,000 | $67,539,000 | $177,468,000 | $355,970,000 |
| Total Equity Gross Minority Interest | $241,540,000 | $67,539,000 | $177,468,000 | $355,970,000 |
| Stockholders Equity | $241,540,000 | $67,539,000 | $177,468,000 | $355,970,000 |
| Gains Losses Not Affecting Retained Earnings | $-41,000 | $-5,000 | $-13,000 | $-272,000 |
| Other Equity Adjustments | $-41,000 | $-5,000 | $-13,000 | $-272,000 |
| Retained Earnings | $-954,483,000 | $-901,994,000 | $-732,069,000 | $-533,426,000 |
| Preferred Securities Outside Stock Equity | - | - | - | - |
| Other | ||||
| Ordinary Shares Number | $281,987,033 | $119,835,162 | $110,160,684 | $109,044,046 |
| Share Issued | $281,987,033 | $119,835,162 | $110,160,684 | $109,044,046 |
| Tangible Book Value | $241,540,000 | $67,539,000 | $177,468,000 | $355,970,000 |
| Invested Capital | $241,540,000 | $67,539,000 | $177,468,000 | $355,970,000 |
| Working Capital | $213,304,000 | $38,705,000 | $174,590,000 | $351,886,000 |
| Capital Lease Obligations | $2,494,000 | $1,304,000 | $2,165,000 | $3,724,000 |
| Total Capitalization | $241,540,000 | $67,539,000 | $177,468,000 | $355,970,000 |
| Additional Paid In Capital | $1,196,036,000 | $969,526,000 | $909,539,000 | $889,657,000 |
| Capital Stock | $28,000 | $12,000 | $11,000 | $11,000 |
| Common Stock | $28,000 | $12,000 | $11,000 | $11,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $1,180,000 | $0 | $722,000 | $2,165,000 |
| Current Capital Lease Obligation | $1,314,000 | $1,304,000 | $1,443,000 | $1,559,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $5,749,000 | $3,916,000 | $10,752,000 | $5,985,000 |
| Current Accrued Expenses | $13,304,000 | $46,281,000 | $30,108,000 | $15,926,000 |
| Net PPE | $3,807,000 | $2,893,000 | $4,125,000 | $6,059,000 |
| Gross PPE | $3,807,000 | $2,893,000 | $4,125,000 | $6,059,000 |
| Other Properties | $3,807,000 | $2,893,000 | $4,125,000 | $6,059,000 |
| Finished Goods | $263,000 | $0 | - | - |
| Treasury Stock | - | $0 | $0 | $0 |
| Dueto Related Parties Non Current | - | $0 | $700,000 | - |
| Other Short Term Investments | - | - | $0 | $279,915,000 |
| Treasury Shares Number | - | - | - | $0 |
Fetched: 2026-06-22
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-58,290,000 | $-170,631,000 | $-173,779,000 | $-221,692,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-58,135,000 | $-170,491,000 | $-173,164,000 | $-219,987,000 |
| Cash Flow From Continuing Operating Activities | $-58,135,000 | $-170,491,000 | $-173,164,000 | $-219,987,000 |
| Operating Gains Losses | - | - | - | $17,373,000 |
| Investing Activities | ||||
| Capital Expenditure | $-155,000 | $-140,000 | $-615,000 | $-1,705,000 |
| Investing Cash Flow | $-155,000 | $-140,000 | $280,684,000 | $-230,667,000 |
| Cash Flow From Continuing Investing Activities | $-155,000 | $-140,000 | $280,684,000 | $-230,667,000 |
| Financing Activities | ||||
| Repurchase Of Capital Stock | $-633,000 | $0 | $-1,000 | $-4,000 |
| Issuance Of Capital Stock | $215,934,000 | $39,285,000 | $0 | $0 |
| Financing Cash Flow | $215,630,000 | $39,331,000 | $1,045,000 | $506,000 |
| Cash Flow From Continuing Financing Activities | $215,630,000 | $39,331,000 | $1,045,000 | $506,000 |
| Net Other Financing Charges | $-336,000 | $-597,000 | $-149,000 | - |
| Net Common Stock Issuance | $215,301,000 | $39,285,000 | $-1,000 | $-4,000 |
| Common Stock Issuance | $215,934,000 | $39,285,000 | $0 | $0 |
| Net Preferred Stock Issuance | - | - | - | $0 |
| Preferred Stock Issuance | - | - | - | $0 |
| Other | ||||
| End Cash Position | $226,689,000 | $69,349,000 | $200,641,000 | $92,076,000 |
| Beginning Cash Position | $69,349,000 | $200,641,000 | $92,076,000 | $542,224,000 |
| Effect Of Exchange Rate Changes | $0 | $8,000 | $0 | - |
| Changes In Cash | $157,340,000 | $-131,300,000 | $108,565,000 | $-450,148,000 |
| Proceeds From Stock Option Exercised | $665,000 | $643,000 | $1,195,000 | $510,000 |
| Common Stock Payments | $-633,000 | $0 | $-1,000 | $-4,000 |
| Net PPE Purchase And Sale | $-155,000 | $-140,000 | $-615,000 | $-1,705,000 |
| Purchase Of PPE | $-155,000 | $-140,000 | $-615,000 | $-1,705,000 |
| Change In Working Capital | $-19,694,000 | $-23,467,000 | $5,888,000 | $-16,130,000 |
| Change In Other Current Liabilities | $-1,195,000 | $-2,371,000 | $-869,000 | $-436,000 |
| Change In Other Current Assets | $-77,000 | $141,000 | $16,000 | $3,106,000 |
| Change In Payables And Accrued Expense | $-27,636,000 | $11,373,000 | $25,633,000 | $-39,167,000 |
| Change In Accrued Expense | $-30,847,000 | $8,950,000 | $19,162,000 | $-34,867,000 |
| Change In Payable | $3,211,000 | $2,423,000 | $6,471,000 | $-4,300,000 |
| Change In Account Payable | $3,211,000 | $2,423,000 | $6,471,000 | $-4,300,000 |
| Change In Prepaid Assets | $12,924,000 | $3,185,000 | $-18,892,000 | $20,367,000 |
| Change In Inventory | $-373,000 | $-24,889,000 | $0 | - |
| Change In Receivables | $-3,337,000 | $-10,906,000 | $0 | - |
| Changes In Account Receivables | $-3,337,000 | $-10,906,000 | $0 | - |
| Other Non Cash Items | $298,000 | - | - | - |
| Stock Based Compensation | $11,643,000 | $19,788,000 | $18,685,000 | $21,648,000 |
| Depreciation Amortization Depletion | $2,107,000 | $3,113,000 | $2,028,000 | $462,000 |
| Depreciation And Amortization | $2,107,000 | $3,113,000 | $2,028,000 | $462,000 |
| Depreciation | $2,107,000 | $3,113,000 | $2,028,000 | $462,000 |
| Net Income From Continuing Operations | $-52,489,000 | $-169,925,000 | $-198,643,000 | $-241,317,000 |
| Net Investment Purchase And Sale | - | $0 | $281,299,000 | $-228,962,000 |
| Sale Of Investment | - | $0 | $372,501,000 | $69,000,000 |
| Purchase Of Investment | - | $0 | $-91,202,000 | $-297,962,000 |
| Amortization Of Securities | - | $0 | $-1,122,000 | $-2,023,000 |
| Gain Loss On Investment Securities | - | - | - | $17,373,000 |
Fetched: 2026-06-22